Comparative Pharmacology
Head-to-head clinical analysis: EDOXABAN versus LIQUAMAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDOXABAN versus LIQUAMAR.
EDOXABAN vs LIQUAMAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective, direct, reversible inhibitor of factor Xa, blocking the conversion of prothrombin to thrombin, thereby reducing thrombin generation and thrombus formation.
Liquamar (phenprocoumon) is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X in the liver by blocking the reduction of vitamin K to its active hydroquinone form.
60 mg orally once daily
Initial: 0.5-1 mg/kg IV (not to exceed 2 mg). Maintenance: 0.5-2 mg IV q8-12h based on INR.
None Documented
None Documented
Terminal elimination half-life is 10-14 hours. In patients with creatinine clearance 15-50 mL/min, half-life is prolonged to approximately 17-20 hours.
Clinical Note
moderateEdoxaban + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Edoxaban."
Clinical Note
moderateEdoxaban + Benzydamine
"Edoxaban may increase the anticoagulant activities of Benzydamine."
Clinical Note
moderateEdoxaban + Deferasirox
The terminal elimination half-life of phenprocoumon is approximately 5 to 7 days (range 3-10 days). This long half-life results in sustained anticoagulant effect over days, requiring careful monitoring and dose adjustments.
Renal excretion accounts for approximately 50% of the administered dose. Fecal excretion accounts for approximately 40%. Biliary excretion is minimal.
Phenprocoumon is excreted primarily via renal elimination as metabolites (approximately 60-70% of the dose), with about 20% excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Category C
Category C
Anticoagulant
Anticoagulant
"The risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox."